Loading clinical trials...
Loading clinical trials...
A Single Arm Study of Acalabrutinib Combined With Obinutuzumab in Chinese Patients With Treatment-Naive Chronic Lymphocytic Leukemia
Conditions
Interventions
Acalabrutinib
Obinutuzumab
Locations
1
China
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, China
Start Date
April 16, 2024
Primary Completion Date
May 31, 2026
Completion Date
September 30, 2026
Last Updated
May 9, 2024
NCT07277231
NCT05006716
NCT06859424
NCT05254743
NCT01804686
NCT05371808
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions